Czechia· CZ-0255004
SOGROYA
A somapacitan product containing somapacitan, registered in Czechia by Novo Nordisk A/S, Bagsvaerd. The same ATC class is registered in 13 of our 19 countries.
Checked against SÚKL (Czech Republic) on
Informational only — not a medical device.
Where it is registered
Somapacitan is registered in 13 of 19 countries.
Countries holding a registration under ATC H01AC07 (somapacitan), each read from that country’s own register.
- This record: Czechia, from SÚKL (Czech Republic)
- 8 of them publish a price we can compare per daily dose
Somapacitan · ATC H01AC07
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
SÚKL (Czech Republic)- Active substance
- SOMAPACITAN
- Manufacturer
- Novo Nordisk A/S, Bagsvaerd
- Country
- Czechia (CZ)
- ATC code
- H01AC07
- ATC class
- Somapacitan
- Defined daily dose
- 0.6 mg, P
- Reimbursed
- Not published by this register
- Source register
- SÚKL (Czech Republic)
- Last checked
- September 28, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
303 interactions on record for somapacitan.
Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Somapacitan · interactions on record
303 records
- 2 severe
- 296 moderate
- 5 minor
Most severe, free to view
- OmeprazoleA02BC01moderate
- PantoprazoleA02BC02moderate
- LansoprazoleA02BC03moderate
- RabeprazoleA02BC04moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Somapacitan in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumSogroya 10 mg/1.5 mlNovo Nordisk
- SwitzerlandSogroya 10 mg/ 1.5 ml, Injektionslösung im FertigpenNovo Nordisk Pharma AG
- SpainSOGROYA 10 MG/1,5 ML SOLUCION INYECTABLE EN PLUMA PRECARGADANovo Nordisk A/S
- IcelandSogroyaNovo Nordisk A/S*
- PolandSogroyaNovo Nordisk A/S
- SwedenSogroya 10 mg/1,5 ml Injektionsvätska, lösning i förfylld injektionspennaNovo Nordisk A/S
- CanadaSOGROYANOVO NORDISK CANADA INC
- FinlandSogroyaNovo Nordisk A/S
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Sogroya
- Norway · Sogroya
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of SÚKL (Czech Republic). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/2e8b44d5-8c4d-4b73-927c-212293f611f9 GET /v1/drugs/2e8b44d5-8c4d-4b73-927c-212293f611f9?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "INJ SOL PEP",
"source": "sukl",
"strength": "10MG/1,5ML",
"pack_size": "5(5X1)X1,5ML",
"substance": "SOMAPACITAN",
"cz_kod_sukl": "0255004",
"product_type": "BT",
"substance_codes": "20728",
"registration_state": "R",
"registration_number": "EU/1/20/1501/002"
}See everything about somapacitan.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.